•HRES 360 IH 
Whereas in the United States, approximately 1,100,000 peo-
ple are living with HIV/AIDS and someone is newly in-
fected with HIV every 9.5 minutes; 
Whereas one in five individuals living with HIV is unaware 
of their infection, and significant disparities persist 
across different communities and populations with regard 
to incidence, access to treatment, and health outcomes; 
Whereas the United States is heavily engaged in both inter-
national and domestic efforts to address the HIV/AIDS 
epidemic, including the President’s Emergency Plan for 
AIDS Relief (PEPFAR), the Global Fund to Fight 
AIDS, Tuberculosis (TB), and Malaria, the Ryan White 
Comprehensive AIDS Resources Emergency (CARE) Act, 
the AIDS Drug Assistance Program (ADAP), the Hous-
ing Opportunities for People With AIDS (HOPWA) Pro-
gram, and AIDS research at the National Institutes of 
Health (NIH); 
Whereas the biennial IAS Conference on HIV Pathogenesis, 
Treatment, and Prevention is the world’s largest open 
scientific conference on HIV/AIDS, attracting about 
5,000 delegates from around the world; 
Whereas together with the International AIDS Conference, 
which will next be held in Washington, DC, from July 
22, 2012, through July 27, 2012, it provides the world’s 
leading scientists, clinicians, policymakers, and commu-
nity leaders with a unique opportunity to examine the lat-
est developments in HIV research and how scientific ad-
vances can practically guide the national and global re-
sponse to HIV/AIDS; 
Whereas IAS 2011 takes place from July 17, 2011, through 
July 20, 2011, in Rome, Italy, organized by the Inter-
VerDate Mar 15 2010 
01:06 Jul 21, 2011
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR360.IH
HR360
rfrederick on DSKD9S0YB1PROD with BILLS
•HRES 360 IH 
national AIDS Society in partnership with the Istituto 
Superiore di Sanita` (ISS), the leading technical and sci-
entific body of the Italian National Health Service; 
Whereas this year’s conference is of particular importance 
given the first documented case of a patient being cured 
of HIV infection and global resurgence of tuberculosis 
(TB), including multidrug-resistant tuberculosis (MDR– 
TB) and extensively drug-resistant tuberculosis (XDR– 
TB); 
Whereas known as the ‘‘Berlin Patient’’, Timothy Ray 
Brown’s remarkable story appeared in the December 8, 
2010, article entitled, ‘‘Evidence for the cure of HIV in-
fection by CCR5∆32/∆32 stem cell transplantation’’, in 
the scientific journal Blood; 
Whereas according to the Centers for Disease Control and 
Prevention (CDC), TB is the leading cause of death 
among persons with HIV worldwide and XDR–TB is re-
sistant to the most powerful first-line and second-line 
drugs; 
Whereas the improper treatment of TB in HIV-infected indi-
viduals perpetuates the spread of this infectious disease 
as well as bolsters drug resistance, which poses a tremen-
dous threat to public health in the United States and 
abroad; 
Whereas improved efforts to prevent and treat TB among 
people living with HIV, including the development of new, 
transformational antibiotic drugs, can save millions of 
lives; 
Whereas several organizations, including small business bio-
technology companies, developing therapeutic vaccines 
VerDate Mar 15 2010 
01:06 Jul 21, 2011
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR360.IH
HR360
rfrederick on DSKD9S0YB1PROD with BILLS
•HRES 360 IH 
and other immune-based therapies are presenting updates 
on their clinical research at IAS 2011; 
Whereas the National Association of People With AIDS 
(NAPWA) and Health People, the first community-based 
organization for women infected with HIV in the United 
States, are hosting the NAPWA ‘‘Treatment Horizons: 
Pathways to a Functional Cure’’ satellite symposium, 
which is officially affiliated with IAS 2011; and 
Whereas therapeutic vaccine candidates and immune-based 
therapies such as those being presented at IAS 2011 may 
lead to a ‘‘functional cure’’ for HIV/AIDS: Now, there-
fore, be it 
Resolved, That the House of Representatives— 
(1) supports the sixth IAS Conference on HIV 
Pathogenesis, Treatment, and Prevention; 
(2) recognizes that continued commitment by 
the United States to HIV/AIDS research, preven-
tion, and treatment programs is crucial to protecting 
global health; 
(3) seeks to prevent the transmission of HIV, 
as well as tuberculosis (TB), multidrug-resistant tu-
berculosis (MDR–TB), and extensively drug-resist-
ant tuberculosis (XDR–TB), and improve health 
outcomes in people living with HIV/AIDS; 
(4) commits to helping support a strong global 
response to HIV/AIDS, protect the rights of those 
infected, and increase access to testing, treatment, 
and care; 
VerDate Mar 15 2010 
02:42 Jul 21, 2011
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\HR360.IH
HR360
rfrederick on DSKD9S0YB1PROD with BILLS
•HRES 360 IH 
(5) encourages the ongoing development of in-
novative therapies and advances in clinical treatment 
for HIV/AIDS, especially by small business bio-
technology firms, and new, transformational anti-
biotic drugs to treat infectious diseases such as TB, 
MDR–TB, and XDR–TB; and 
(6) urges scientists, health care providers, pol-
icymakers, community leaders, and all individuals 
committed to ending the HIV/AIDS pandemic to at-
tend the XIX International AIDS Conference (AIDS 
2012). 
Æ 
VerDate Mar 15 2010 
01:06 Jul 21, 2011
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\HR360.IH
HR360
rfrederick on DSKD9S0YB1PROD with BILLS